Survivorship medicine has never been in more demand, but questions regarding reimbursement remain. According to Jennifer Malin, MD, PhD, Medical Director, Oncology and Care Management, Anthem, if cancer survivorship models are to succeed, they will need to integrate into new healthcare delivery models, with less focus on cost and more on improving care coordination.
The investigational biosimilar (LA-EP2006) to the reference drug pegfilgrastim (Neulasta) has demonstrated similar results in patients with breast cancer who are receiving the regimen known as TAC (docetaxel, doxorubicin, and cyclophosphamide), according to data from the multicenter, randomized, double-blind PROTECT 2 trial.
Although the cost of treating newly diagnosed patients with multiple myeloma is greatly increased with the use of 3 drugs, 2-drug regimens should no longer be considered adequate, according to new data presented at ASH 2015.
Patients with previously treated metastatic urothelial cancer had response rates that exceeded historical standards when treated with an investigational immunotherapeutic agent, updated results of a large phase 2 clinical trial showed. Treatment with the PD-1 ligand 1 (PD-L1) inhibitor atezolizumab led to an overall response rate of 15% in 311 patients, including a 26% rate among patients who had the highest levels of PD-L1 expression. Historical data have demonstrated response rates of about 10% for second-line therapy and beyond.
  • Imbruvica Now FDA Approved for First-Line Treatment of Patients with CLL
  • Gazyva Approved for the Treatment of Relapsed or Refractory Follicular Lymphoma
  • Ibrance Receives an Expanded Indication in Breast Cancer
  • Kyprolis Receives New Indication for Relapsed or Refractory Multiple Myeloma
  • FDA Grants Priority Review for Venetoclax as a Potential New Treatment for CLL
  • ASCO Issues Guidelines for Developing Clinical Pathways That Promote Value-Based Care
  • Second Cancer Risk Is High After Hodgkin Lymphoma
  • Cancer Screening May Not Save Lives, a New Analysis Suggests
A recently published perspective in Value-Based Cancer Care criticized the National Comprehensive Cancer Network (NCCN) Evidence Blocks initiative. Regrettably, that perspective is extremely misleading and is full of innuendo and misuse of statistics.
A liquid biopsy using phlebotomy blood samples can identify phenotypes and genomic characteristics of circulating tumor cells that may personalize treatment selection for men with advanced prostate cancer, according to the results of a study presented by Howard I. Scher, MD, Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, NY, at the 2016 ASCO Genitourinary Cancers Symposium.
A panel of 4 blood-derived biomarkers showed promise as an aid to early detection of colo­rectal cancer (CRC). The panel yielded a negative predictive value exceeding 90% for CRC, the combination of CRC and high-risk adenomas, and colorectal plus other cancers. The biomarker assay demonstrated fair to good performance characteristics, associated with the receiver operating characteristic (ROC) curve ranging between 0.70 and 0.80.
Elderly patients with Philadelphia-negative B-cell acute lymphoblastic leukemia (ALL) have overall poor outcomes with current therapies. Results of a new study presented at ASH 2015 suggest that frontline treatment with the investigational antibody-drug conjugate inotuzumab ozogamicin in combination with deintensified chemotherapy is a good option for older patients with this disease.
Page 1 of 3
Results 1 - 10 of 21
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology